UBS Maintains Neutral on CME Group, Raises Price Target to $270

Benzinga Newsdesk www.benzinga.com Positive 59.6%

Neg 0% Neu 0% Pos 59.6%

UBS analyst Alex Kramm maintains CME Group (NASDAQ:CME) with a Neutral and raises the price target from $260 to $270.

Comments

No comments yet. Be the first!